{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260624345655/en/European-Commission-Approves-KEYTRUDA%C2%AE-pembrolizumab-Plus-Padcev%C2%AE-enfortumab-vedotin-ejfv-as-First-PD-1-Inhibitor-Plus-Antibody-Drug-Conjugate-Regimen-for-Adults-With-Cisplatin-Ineligible-Resectable-Muscle-Invasive-Bladder-Cancer", "message": "News view counter 813888 successfully enlarged"}